Update shared on 02 Dec 2025
The average analyst price target for IDEXX Laboratories has been raised, reflecting a series of upward revisions. Several targets now surpass $750, as analysts cite stronger-than-expected Q3 results and a constructive outlook on growth, innovation, and recurring revenues.
Analyst Commentary
Recent analyst commentary on IDEXX Laboratories presents a blend of optimism about the company's prospects and caution regarding its valuation and future growth trajectory.
Bullish Takeaways- Several bullish analysts have increased their price targets, now surpassing $750, citing a strong third quarter and raised guidance for 2025.
- There is increased conviction in IDEXX's long-term growth potential, supported by a robust innovation pipeline that is considered one of the most compelling in the company's history.
- The company's strong execution in both U.S. and international recurring diagnostic businesses highlights a large market opportunity and the ability to capitalize on it through effective growth levers.
- Recurring revenues, especially from Companion Animal Group diagnostics, are expected to accelerate over the next few years, aided by resilient visit volumes and the strengthening “IDEXX premium.”
- Some cautious analysts maintain neutral ratings, noting that while performance was impressive in the latest quarter, current stock valuation may already reflect much of this recent strength.
- Concerns have been raised about the stock trading at a significant premium to earnings estimates, suggesting that future outperformance may be needed to justify present multiples.
- Although macroeconomic conditions are showing modest improvement, risks remain that could temper near-term growth expectations.
- There is a view that while current trends are robust, a step-down in price realization could limit upside in certain recurring revenue streams over the longer term.
What's in the News
- Completed a repurchase of 411,180 shares, representing 0.51% of outstanding shares, for $241.57 million between July 1 and September 30, 2025. The total buyback since August 1999 now stands at 73,923,960 shares, or 61.91% of shares, for $7.70 billion (Key Developments).
- Raised 2025 financial guidance: revenue is now expected to be between $4,270 million and $4,300 million, up from the previous range of $4,205 million to $4,280 million (Key Developments).
- The company anticipates reported revenue growth between 9.6% and 10.3%, an increase from the earlier forecast of 7.7% to 9.7% (Key Developments).
- Projected 2025 EPS has been revised upward to $12.81–$13.01, from prior guidance of $12.40–$12.76, with reported EPS growth now estimated at 20% to 22% (Key Developments).
Valuation Changes
- Fair Value Estimate remains essentially unchanged and stays at $754.83 per share.
- Discount Rate has risen slightly, moving from 7.72% to 7.74%.
- Revenue Growth projection is nearly flat, with a minor decrease from 9.20% to 9.20%.
- Net Profit Margin shows a negligible uptick and increases from 25.47% to 25.48%.
- Future P/E Ratio is up marginally, rising from 51.19x to 51.22x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.